why choose us

300×250 Ad Slot

Drug FDA Status

Showing 120 of 196 result(s) (Page 12 of 20)
Drug Name: Miplyffa

Active Ingredient: arimoclomol

Approval Date: 2024-09-20

Description: To treat Niemann-Pick disease type C
Press Release
Drug Trials Snapshot

Drug Name: Ebglyss

Active Ingredient: lebrikizumab-lbkz

Approval Date: 2024-09-13

Description: To treat moderate-to-severe atopic dermatitis
Drug Trials Snapshot

Drug Name: Lazcluze

Active Ingredient: lazertinib

Approval Date: 2024-08-19

Description: To treat non-small cell lung cancer
Drug Trials Snapshot

Drug Name: Niktimvo

Active Ingredient: axatilimab-csfr

Approval Date: 2024-08-14

Description: To treat chronic graft-versus-host disease (cGVHD)
Drug Trials Snapshot

Drug Name: Livdelzi

Active Ingredient: seladelpar

Approval Date: 2024-08-14

Description: To treat primary biliary cholangitis (PBC)
Drug Trials Snapshot

Drug Name: Nemluvio

Active Ingredient: nemolizumab-ilto

Approval Date: 2024-08-12

Description: To treat prurigo nodularis
Drug Trials Snapshot

Drug Name: Yorvipath

Active Ingredient: palopegteriparatide

Approval Date: 2024-08-09

Description: To treat hypoparathyroidism
Drug Trials Snapshot

Drug Name: Voranigo

Active Ingredient: vorasidenib

Approval Date: 2024-08-06

Description: To treat Grade 2 astrocytoma or oligodendroglioma
Drug Trials Snapshot

Drug Name: Leqselvi

Active Ingredient: deuruxolitinib

Approval Date: 2024-07-25

Description: To treat severe alopecia areata
Drug Trials Snapshot

Drug Name: Kisunla

Active Ingredient: donanemab-azbt

Approval Date: 2024-07-02

Description: To treat Alzheimer’s disease
Drug Trials Snapshot

300×250 Ad Slot